Jade Biosciences prices $150M public offering of 10M shares at $15/share

Jade Biosciences, Inc.

Priced public offering of 10,000,000 shares of common stock at $15.00 per share for gross proceeds of $150.0M.
Net proceeds expected ~$140.3M (~$161.5M if underwriters’ 30-day option for 1.5M additional shares is exercised).
Intends use net proceeds for clinical trials, preclinical studies, manufacturing, R&D, capex, working capital, and general corporate purposes.
Jefferies, TD Cowen, UBS Investment Bank acting as joint book-running managers; offering expected to close June 5, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.